MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals Total Shareholders Equity 2011-2025 | ZYNE
Annual Total Shareholders Equity Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.2 M | 70.9 M | 60.1 M | 75.6 M | 57.6 M | 60.9 M | 29.6 M | 39.7 M | -8.05 M | -4.36 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 75.6 M | -8.05 M | 42.8 M |
Quarterly Total Shareholders Equity Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 M | 39 M | 46.2 M | 52.8 M | 57.2 M | 65.2 M | 70.9 M | 78.7 M | 87.7 M | 95.7 M | 60.1 M | 60.1 M | 60.1 M | 60.1 M | 75.6 M | 75.6 M | 75.6 M | 75.6 M | 57.6 M | 57.6 M | 57.6 M | 57.6 M | 60.9 M | 60.9 M | 60.9 M | 60.9 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 39.7 M | 39.7 M | 39.7 M | 39.7 M | -8.05 M | -8.05 M | -8.05 M | - | -4.36 M | - | - | - | -3.56 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 95.7 M | -8.05 M | 48.3 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.19 | -9.16 % | $ 128 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
2.13 B | $ 4.49 | -1.75 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
649 M | $ 12.43 | -1.58 % | $ 636 M | USA |
 |
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.59 | 0.05 % | $ 2.05 B |  France |
 |
OrganiGram Holdings
OGI
|
300 M | $ 1.79 | 1.7 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
263 M | $ 5.28 | -10.14 % | $ 695 M | USA |
 |
Evolus
EOLS
|
5.52 M | $ 6.9 | 0.73 % | $ 428 M | USA |
 |
Harrow Health
HROW
|
70.8 M | $ 50.09 | -0.14 % | $ 1.63 B | USA |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 1.29 | -2.65 % | $ 22.5 M |  China |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 0.86 | 6.83 % | $ 20.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.61 | -0.82 % | $ 4.48 M | USA |
 |
Bausch Health Companies
BHC
|
-1.02 B | $ 7.2 | 0.07 % | $ 2.63 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 4.12 | -1.9 % | $ 57.9 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.4 | 2.56 % | $ 324 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 26.51 | 1.88 % | $ 1.23 B | USA |
 |
Sundial Growers
SNDL
|
270 M | $ 1.73 | -2.26 % | $ 3.37 M | Canada |
 |
cbdMD
YCBD
|
1.96 M | $ 1.68 | 5.66 % | $ 7.25 M | USA |
 |
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
4.32 B | $ 13.82 | 0.62 % | $ 1.9 B | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | $ 0.52 | -15.45 % | $ 8.24 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.51 | -1.96 % | $ 136 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
138 M | $ 9.94 | 0.42 % | $ 706 M | USA |
 |
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
137 M | $ 5.84 | -1.02 % | $ 238 M | USA |
 |
SCYNEXIS
SCYX
|
73 M | $ 0.59 | -1.34 % | $ 28.2 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
3.32 B | $ 9.6 | -5.42 % | $ 5.93 B | Canada |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 1.74 | 2.35 % | $ 18.2 M | USA |